Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0
- PMID: 28913963
- PMCID: PMC5639362
- DOI: 10.1002/pds.4295
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0
Erratum in
-
Erratum.Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1570. doi: 10.1002/pds.4353. Pharmacoepidemiol Drug Saf. 2017. PMID: 29205684 Free PMC article. No abstract available.
Abstract
Purpose: Defining a study population and creating an analytic dataset from longitudinal healthcare databases involves many decisions. Our objective was to catalogue scientific decisions underpinning study execution that should be reported to facilitate replication and enable assessment of validity of studies conducted in large healthcare databases.
Methods: We reviewed key investigator decisions required to operate a sample of macros and software tools designed to create and analyze analytic cohorts from longitudinal streams of healthcare data. A panel of academic, regulatory, and industry experts in healthcare database analytics discussed and added to this list.
Conclusion: Evidence generated from large healthcare encounter and reimbursement databases is increasingly being sought by decision-makers. Varied terminology is used around the world for the same concepts. Agreeing on terminology and which parameters from a large catalogue are the most essential to report for replicable research would improve transparency and facilitate assessment of validity. At a minimum, reporting for a database study should provide clarity regarding operational definitions for key temporal anchors and their relation to each other when creating the analytic dataset, accompanied by an attrition table and a design diagram. A substantial improvement in reproducibility, rigor and confidence in real world evidence generated from healthcare databases could be achieved with greater transparency about operational study parameters used to create analytic datasets from longitudinal healthcare databases.
Keywords: Transparency; healthcare databases; longitudinal data; methods; pharmacoepidemiology; replication; reproducibility.
© 2017 The Authors. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons Ltd.
Figures
Comment in
-
Guidance to reinforce the credibility of health care database studies and ensure their appropriate impact.Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1013-1017. doi: 10.1002/pds.4305. Pharmacoepidemiol Drug Saf. 2017. PMID: 28913965 No abstract available.
Similar articles
-
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0.Value Health. 2017 Sep;20(8):1009-1022. doi: 10.1016/j.jval.2017.08.3018. Epub 2017 Sep 15. Value Health. 2017. PMID: 28964431
-
Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions.Nat Commun. 2022 Aug 31;13(1):5126. doi: 10.1038/s41467-022-32310-3. Nat Commun. 2022. PMID: 36045130 Free PMC article.
-
Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases.Clin Pharmacol Ther. 2016 Mar;99(3):325-32. doi: 10.1002/cpt.329. Clin Pharmacol Ther. 2016. PMID: 26690726 Free PMC article.
-
Healthcare Databases for Drug Safety Research: Data Validity Assessment Remains Crucial.Drug Saf. 2018 Sep;41(9):829-833. doi: 10.1007/s40264-018-0673-z. Drug Saf. 2018. PMID: 29714003 Review.
-
Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review.Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5787. doi: 10.1002/pds.5787. Pharmacoepidemiol Drug Saf. 2024. PMID: 38724471
Cited by
-
The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives.Drug Des Devel Ther. 2023 Sep 6;17:2691-2725. doi: 10.2147/DDDT.S424991. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 37701048 Free PMC article.
-
Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study.Osteoporos Int. 2022 May;33(5):1155-1164. doi: 10.1007/s00198-021-06291-w. Epub 2022 Jan 15. Osteoporos Int. 2022. PMID: 35032187 Free PMC article.
-
The hope, hype and reality of Big Data for pharmacovigilance.Ther Adv Drug Saf. 2018 Jan;9(1):5-11. doi: 10.1177/2042098617736422. Epub 2017 Oct 31. Ther Adv Drug Saf. 2018. PMID: 29318002 Free PMC article. No abstract available.
-
Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):245-252. doi: 10.1002/pds.4381. Epub 2018 Jan 11. Pharmacoepidemiol Drug Saf. 2018. PMID: 29327451 Free PMC article. No abstract available.
-
Validation of an Algorithm to Identify Venous Thromboembolism in Health Insurance Claims Data Among Patients with Rheumatoid Arthritis.Clin Epidemiol. 2023 Jun 1;15:671-682. doi: 10.2147/CLEP.S402360. eCollection 2023. Clin Epidemiol. 2023. PMID: 37284517 Free PMC article.
References
-
- Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. Apr 2005;58(4):323‐337. - PubMed
-
- Califf RM, Robb MA, Bindman AB, et al. Transforming Evidence Generation to Support Health and Health Care Decisions. N Engl J Med. 2016;375(24):2395‐2400. - PubMed
-
- Psaty BM, Breckenridge AM. Mini‐Sentinel and regulatory science‐‐big data rendered fit and functional. N Engl J Med. Jun 5. 2014;370(23):2165‐2167. - PubMed
-
- Oliveira JL, Lopes P, Nunes T, et al. The EU‐ADR Web Platform: delivering advanced pharmacovigilance tools. Pharmacoepidemiol Drug Saf. 2013 May. 2013;22(5):459‐467. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical